Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp to Offer Ipsogen's JAK2 Leukemia Assay in US via CLIA Labs

NEW YORK (GenomeWeb News) - LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement, Ispogen said today.
 
Ipsogen, based in Marseilles, France, said the assay classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights. 
 
The license will allow LabCorp to offer the test, which is registered as an IVD in Europe, through its CLIA-registered US labs.
 
The company said that a “high proportion” of individuals with myeloproliferative disorders have a dominant mutation of the JAK2 gene.
 
Financial terms of the agreement were not released.
 
Last month, Ispogen granted Warnex rights to offer the JAK2 assay in Canada.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.